Study of Safety and Tolerability of DCR HBVS

Inclusion Criteria: * Healthy at the time of screening as determined by medical evaluation. * Capable of giving informed consent. * 12-lead ECG within normal limits or with no clinically significant abnormalities. * Negative screen for alcohol or drugs of abuse. * Non-smokers for at least 3 months with a negative urinary cotinine concentration at screening. * BMI within range 18.0 - 32.0 kg/m2 (inclusive). * Female participants not pregnant, not breastfeeding, and not of childbearing potential or willing to follow contraceptive guidance. * Chronic hepatitis B infection (Group B and C only). * Clinical history compatible with compensated liver disease with no evidence of cirrhosis (Group B and C only). * Continuously on nucleotides (NUC) therapy for at least 12 weeks prior to screening (Group C only). Exclusion Criteria: * History of any medical condition that may interfere with the absorption, distribution, or elimination of study drug. * Poorly controlled or unstable hypertension. * History of diabetes mellitus treated with insulin or hypoglycemic agents. * History of asthma requiring hospital admission within the preceding 12 months. * Evidence of G-6-PD deficiency. * Currently poorly controlled endocrine conditions, excluding thyroid conditions. * History of multiple drug allergies or history of allergic reaction to an oligonucleotide or GalNAc. * Clinically relevant surgical history. * Use of prescription medications (excluding contraception for women) within 4 weeks prior to the administration of study intervention. * Use of clinically relevant over-the-counter medication or supplements (excluding routine vitamins) within 7 days of first dosing. * Has received an investigational agent within the 3 months prior to dosing or is in follow-up of another study. * Antiviral therapy (other than entecavir or tenofovir) within 3 months of screening or treatment with interferon in the last 3 years (Group B and C only). * Use within the last 6 months of anticoagulants or systemically administered corticosteroids, immunomodulators, or immunosuppressants (Group B and C only).